Edition:
United States

Acceleron Pharma Inc (XLRN.O)

XLRN.O on Consolidated Issue listed on NASDAQ Global Market

26.64USD
23 Mar 2017
Change (% chg)

$-0.21 (-0.78%)
Prev Close
$26.85
Open
$26.96
Day's High
$27.26
Day's Low
$26.36
Volume
204,842
Avg. Vol
425,522
52-wk High
$41.69
52-wk Low
$23.07

Latest Key Developments (Source: Significant Developments)

Acceleron to initiate phase 2 trial of ACE-083 in charcot-marie-tooth neuromuscular disease
Thursday, 16 Mar 2017 07:00am EDT 

Acceleron Pharma Inc - : Acceleron announces plans to initiate a phase 2 trial of ACE-083 in charcot-marie-tooth neuromuscular disease and host educational webinar .Second phase 2 study for ACE-083 expected to begin 2H 2017.  Full Article

Acceleron Q4 loss per share $0.51
Wednesday, 1 Mar 2017 07:00am EST 

Acceleron Pharma Inc : Acceleron reports fourth quarter and year ended 2016 operational and financial results . Acceleron Pharma Inc says outlined plans to initiate several new clinical trials in 2017 . Acceleron Pharma Inc says luspatercept phase 3 trials to complete enrollment in both MDS and beta-thalassemia trials in 2H 2017 . Qtrly loss per share $0.51 .Qtrly collaboration revenue $3.4 million versus $3.8 million.  Full Article

Acceleron Pharma reports Q3 financial and operational results
Thursday, 3 Nov 2016 04:05pm EDT 

Acceleron Pharma Inc : Acceleron Pharma Inc qtrly earnings per share $0.55 .Acceleron Pharma reports third quarter 2016 financial and operational results.  Full Article

Acceleron:Habib Dable named president and ceo
Tuesday, 27 Sep 2016 04:01pm EDT 

Acceleron Pharma Inc : Acceleron announces retirement of John Knopf as president and ceo; Habib Dable named as successor . Habib Dable appointed as president and ceo .Acceleron Pharma Inc says Habib Dable will assume ceo role effective December 1, 2016.  Full Article

Acceleron Pharma Q2 loss per share $0.59
Thursday, 4 Aug 2016 07:00am EDT 

Acceleron Pharma Inc : Acceleron Pharma reports second quarter 2016 financial and operational results . Q2 loss per share $0.59 .Q2 earnings per share view $-0.50 -- Thomson Reuters I/B/E/S.  Full Article

Acceleron announces ACE-083 phase 1 results
Friday, 8 Jul 2016 07:00am EDT 

Acceleron Pharma Inc : Announces ACE-083 phase 1 results at 14th International Congress On Neuromuscular Diseases . ACE-083 increased muscle volume of tibialis anterior muscle by 8.9% in healthy volunteers .Acceleron intends to advance ACE-083 into a phase 2 clinical trial in patients with FSHD in second half of 2016..  Full Article

Acceleron, Celgene says data with Luspatercept show increases in hemoglobin levels
Friday, 10 Jun 2016 07:00am EDT 

Acceleron Pharma Inc : Acceleron and Celgene announce updated results from an ongoing Phase 2 study of Luspatercept in beta-thalassemia presented at the 21st congress of the European Hematology Association . Longer term data with investigational drug Luspatercept show sustained increases in hemoglobin levels, reduced transfusion burden . Results showed 51% of patients with lower risk MDS treated with Luspatercept (n=49) achieved increased hemoglobin levels .Results showed 36% of patients achieved a hemoglobin increase of at least 1.5 g/dl in Luspatercept 3-month base study.  Full Article

Acceleron Announces Proposed Public Offering of Common Stock
Monday, 4 Jan 2016 04:58pm EST 

Acceleron Pharma Inc:intends to offer and sell, subject to market and other conditions, $150 million of its common stock in an underwritten public offering.As part of this offering Acceleron intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent of the number of shares sold.All of the shares in the offering are to be sold by Acceleron.Morgan Stanley, Leerink Partners LLC and UBS Investment Bank are acting as joint book-running managers for the offering.JMP Securities is acting as the lead manager.Acceleron intends to use net proceeds from the offering to conduct clinical trials and associated activities in connection with ACE-083 and Acceleron's other potential therapeutic candidates, including antibodies and proteins from Acceleron's IntelliTrap platform.to further expand Acceleron's research and development efforts, and for general and administrative expenses, potential future development programs, capital expenditures and working capital and other general corporate purposes.  Full Article

Celgene Corporation and Acceleron Pharma Inc announces FDA granted Fast Track Designation to luspatercept for treatment of anemia
Monday, 7 Dec 2015 07:00am EST 

Celgene Corporation and Acceleron Pharma Inc:Announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to luspatercept for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (MDS).Fast Track program of the FDA is designed to facilitate the development, and expedite the review, of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs.  Full Article

Celgene Corporation and Acceleron Pharma Inc announces FDA fast track designation granted to Luspatercept
Monday, 18 May 2015 07:30am EDT 

Celgene Corporation and Acceleron Pharma Inc:Says FDA has granted Fast Track designations to luspatercept for two separate indications; the use of luspatercept for the treatment of patients with transfusion dependent beta-thalassemia and the use of luspatercept for the treatment of patients with non-transfusion dependent beta-thalassemia.Says Celgene and Acceleron are jointly developing luspatercept.  Full Article

More From Around the Web

BRIEF-Acceleron to initiate phase 2 trial of ACE-083 in charcot-marie-tooth neuromuscular disease

* Acceleron announces plans to initiate a phase 2 trial of ACE-083 in charcot-marie-tooth neuromuscular disease and host educational webinar